The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C
Record ID 32010000279
English
Authors' recommendations:
New evidence supported existing evidence of some benefit from AchEIs for Alzheimer's disease. There was weaker evidence for benefit from memantine. Cost-effectiveness estimates are highly uncertain and very sensitive to change.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.hta.ac.uk/2177
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Alzheimer Disease
- Memantine
- Galantamine
- Donepezil
- Rivastigmine
- Neuroprotective Agents
- Dopamine Agents
- Models, Economic
- Cholinesterase Inhibitors
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2012 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.